XERS: Xeris Biopharma Holdings, Inc. Stock

by  •  • Comments Off on XERS: Xeris Biopharma Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 766.34
Enterprise Value ($M) 937.67
Book Value ($M) -35.13
Book Value / Share -0.22
Price / Book -21.82
NCAV ($M) -187.09
NCAV / Share -1.17
Price / NCAV -4.10

Profitability (mra)
Return on Invested Capital (ROIC) -0.19
Return on Assets (ROA) -0.13
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.17
Current Ratio 1.72

Balance Sheet (mrq) ($M)
Current Assets 163.49
Assets 315.45
Liabilities 350.58
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 203.07
Operating Income -33.65
Net Income -54.84
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -36.98
Cash from Investing 4.88
Cash from Financing 36.17

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPOR
2025-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION R
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-15 321,744 1,601,158 20.09
2025-05-14 598,386 2,128,123 28.12
2025-05-13 300,759 1,421,266 21.16
2025-05-12 474,568 2,711,015 17.51

(click for more detail)

Similar Companies
VTYX – Ventyx Biosciences, Inc. VYGR – Voyager Therapeutics, Inc.
XBIT – XBiotech Inc. XLO – Xilio Therapeutics, Inc.
YMAB – Y-mAbs Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io